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Background: As a part of the longitudinal Chronic Obstructive Pulmonary Disease (COPD) study, Subpopulations and
Intermediate Outcome Measures in COPD study (SPIROMICS), blood samples are being collected from 3200 subjects
with the goal of identifying blood biomarkers for sub-phenotyping patients and predicting disease progression. To
determine the most reliable sample type for measuring specific blood analytes in the cohort, a pilot study was
performed from a subset of 24 subjects comparing serum, Ethylenediaminetetraacetic acid (EDTA) plasma, and EDTA
plasma with proteinase inhibitors (P100™).
Methods: 105 analytes, chosen for potential relevance to COPD, arranged in 12 multiplex and one simplex platform
(Myriad-RBM) were evaluated in duplicate from the three sample types from 24 subjects. The reliability coefficient and
the coefficient of variation (CV) were calculated. The performance of each analyte and mean analyte levels were
evaluated across sample types.
Results: 20% of analytes were not consistently detectable in any sample type. Higher reliability and/or smaller CV were
determined for 12 analytes in EDTA plasma compared to serum, and for 11 analytes in serum compared to EDTA
plasma. While reliability measures were similar for EDTA plasma and P100 plasma for a majority of analytes, CV was
modestly increased in P100 plasma for eight analytes. Each analyte within a multiplex produced independent
measurement characteristics, complicating selection of sample type for individual multiplexes.
Conclusions: There were notable detectability and measurability differences between serum and plasma. Multiplexing
may not be ideal if large reliability differences exist across analytes measured within the multiplex, especially if values
differ based on sample type. For some analytes, the large CV should be considered during experimental design, and
the use of duplicate and/or triplicate samples may be necessary. These results should prove useful for studies evaluating
selection of samples for evaluation of potential blood biomarkers.
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SPIROMICS is a longitudinal, multi-center, observa-
tional study with two major goals: 1) to provide robust
criteria for sub-classifying COPD participants into
groups to evaluate therapeutic efficacy during clinical
trials; and 2) to identify biomarkers to use as intermedi-
ate outcomes to predict clinical benefit reliably during
therapeutic trials [1]. SPIROMICS is enrolling 3200 par-
ticipants who will undergo a baseline and three annual
follow up visits (four total over three years). Visits will
include detailed clinical evaluation. Collection of blood
specimens occurs at baseline, and during visits 2 and 4.
Blood analytes will be measured to determine whether
they may provide a picture of COPD clinical phenotypes
relevant to the two broad goals of the study.
It is well-appreciated that some blood analytes are
more reliably measured in one sample type compared to
others, e.g., serum versus plasma, and that absolute
levels of analytes can vary depending upon the nature of
blood processing [2-5]. During coagulation in serum
samples, clot formation removes proteins from the blood
sample (e.g., fibrinogen) and platelet activation releases
proteins such as proinflammatory cytokines and various
metabolites, which can alter analyte levels relative to
plasma. Platelet activation can also affect measured
levels of analytes in plasma, despite the addition of
additives that prevent clot formation. This effect is due
to release of the analyte from the platelets during pro-
cessing [6]. Interactions between platelets and platelet
mediators with leukocytes may cause leukocytes to re-
lease mediators as well. Furthermore, protein/analyte
degradation during sample preparation and storage can
also affect analyte measurements.
A variety of analytes of potential interest to COPD
pathogenesis are known to have different values in
plasma and serum (e.g., fibrinogen, matrix metallopro-
teinases, cytokines). Hence, the choice of blood sample
type for analyte quantification is important for SPIRO-
MICS [7,8]. To maximize the types of analytes and as-
says that can ultimately be performed in this cohort,
serum, EDTA plasma, and ETDA plasma plus proteinase
inhibitors (P100™) specimens are all being collected in
SPIROMICS. Because there will be many samples
collected over multiple time points, selecting the most
reliable blood sample type for each analyte will improve
reliability, longitudinally and across samples, and will
conserve resources.
The choice of measurement platform is also of crucial
importance. Methods for blood analyte analysis vary
from routine ELISA-based, single-analyte measurements
to large-scale proteomics and metabolomics analyses
that measure thousands of analytes simultaneously.
Intermediate coverage platforms, such as ELISA-based
methods conducted via multiplexing, e.g., Luminex™(Luminex Corp, Austin, TX), are also viable options [9].
While the sensitivity of assays measuring individual ana-
lytes is likely to be higher than multiplex assays, single
analyte analysis is expensive in terms of sample usage
(volume) and cost per analyte. The purpose of this pilot
study was to use the multiple types of blood samples
collected within SPIROMICS to determine whether
certain groups of analytes measured via multiplexing can
be measured more reliably in one sample type versus
another. SPIROMICS investigators selected a battery of
analytes that were of interest to the goals of SPIROMICS
and analyzed 105 specific analytes grouped in 12 multi-
plexes, plus a simplex for microalbumin, analyzed in
serum, EDTA plasma and P100 plasma.
Methods
Sample collection
Blood is being collected from SPIROMICS participants
as part of their baseline (initial) visit and additionally 1
and 3 years after the baseline visit. SPIROMICS subjects
are requested to fast after midnight, and blood is drawn
early in the day of the study visit. For the entire SPIRO-
MICS, eight tubes are collected in the following order:
Two 8.5 mL red-stoppered serum tubes [Vacutainer®
Plus plastic serum tube; Becton-Dickinson (BD)
Diagnostics, Franklin Lakes, NJ; product number
367888]; one 10 ml yellow-stoppered tube containing
1.5 mL ACD anticoagulant (BD product number
364606); two 10 mL and one 4 mL lavender-stoppered
tubes containing a sprayed on K2EDTA anticoagulant
(BD product numbers 366643 and 367861); one 8.5 mL
P100 red-stoppered plasma collection tube with a
mechanical separator and sprayed on K2EDTA anti-
coagulant and proprietary protease inhibitor additives
(antiproteases; BD product number 366448); one 2.5 mL
red-stoppered tube with RNA preservation solution
(Paxgene™ RNA, BD; product number 762165). All samples
are processed within one hour of collection, aliquoted, and
frozen at −80°C, shipped to the SPIROMICS Biospecimen
Processing Center and kept frozen at −80°C for future use.
Mean processing times for the samples used in this study
were (in minutes) 39, 32, and 49 for serum, EDTA plasma,
and P100 plasma, respectively. Processing involves immedi-
ate inversion of tubes several times after sample draw and
centrifugation at room temperature at 1100–1300 relative
centrifugal force (RCF) for 10 minutes in a swinging bucket
rotor of 15 minutes in a fixed angle centrifuge for serum
and EDTA plasma, and 2500 RCF for 15–20 minutes or
1100–1600 RCF for 30 minutes for P100 plasma. SPIRO-
MICS protocols require dividing each blood collection tube
into aliquots of 150 μl to minimize freeze-thaw cycles. The
13-plexes run in this pilot study required 3 aliquots each of
serum, P100 plasma and EDTA plasma from each patient.
The aliquots were sent frozen to Myriad-RBM, where they
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for analyte determination according to standard prac-
tices. Each pooled sample was run in duplicate, provid-
ing 2 replicates from the same blood draw for each
blood sample type.Selection of analytes and multiplexes
We first identified priority biomarker candidates based on
known COPD pathophysiology and previously published
literature, then selected from the assays available at
Myriad-RBM, which were primarily multiplexes (Luminex
xMap technology, Myriad-RBM Inc., Austin TX). Each
multiplex measured a number of analytes in addition to the
priority biomarkers. The number of analytes per plex varied
from 1–14 (see Additional file 1: Table S1 and Additional
file 2: Table S2). In total, 105 analytes were evaluated on the
13 plexes, 12 of which were multiplexes.Selection of samples
We next selected samples from 24 SPIROMICS partici-
pants chosen to represent individuals with a range of
disease severity assessed by Global Initiative for Chronic
Obstructive Lung Disease (GOLD) spirometric stage
classification (http://www.goldcopd.org/) at the time of
the blood draw [mean/median age 64/65 years; 12 fe-
males, 12 males; six non-smokers, three at risk smokers,
5 GOLD stage 1 (mild), 4 GOLD stage 2 (moderate), 6
GOLD stage 3 (severe)]. Due to the small sample size,
there was no intent to utilize the data from this study to
correlate analyte levels to clinical phenotype; however,
the range of GOLD spirometric stage provided an op-
portunity to assess some analytes that may have varying
blood levels based on certain disease conditions associ-
ated with COPD.Results received
The measured concentration of each analyte, as well as
the lower limit of quantification (LLOQ), least detectible
concentration (LDD; concentration three standard devia-
tions above diluent blank reading), and the low to high
normal range were provided by Myriad-RBM. The
LLOQ was used as the lowest reliable value. It is defined
as the lowest concentration of analyte reliably detected
and at which the total error meets the laboratory’s re-
quirements for precision. In this case, the laboratory’s
requirements for precision is the concentration of an an-
alyte at which the coefficient of variation of replicate
standard (Myriad-RBM defined) samples is 30%. If a
sample value was below the LLOQ, it was reported as <
LLOQ for that analyte. Rarely, a sample could not be
measured due to technical problems during processing
and these were reported as ND (not determined).Statistical methods: measurability and reliability
For each analyte, identical analyses were carried out for
the three sample types. In the first step, the percentage
of samples below the LLOQ was calculated, and the
number of subjects with both replicates ≥ LLOQ was de-
termined. No further analysis was done on a particular
analyte if one or both replicates were less than LLOQ in
more than 50% of subjects. For the remaining analytes,
descriptive statistics were calculated for the subset of
subjects with both replicate values ≥ LLOQ including
the mean, within-subject standard deviation, reliability
coefficient, and within-subject coefficient of variation
(CV). All statistical analyses were conducted using
SAS version 9.2.
The within-subject and between-subject variance were
calculated from the overall variance using a simple ran-
dom effects linear model with a random subject inter-
cept. The within-subject standard deviation is the square
root of the within-subject variance. The reliability coeffi-
cient is the ratio of the between-subject variance and the
total variance in the samples. Reliability is dependent on
the overall variability of the samples. Thus, for analytes
with very little variability between subjects, small vari-
ation in replicate samples within a subject may result in
a reduced reliability coefficient. Conversely, for analytes
with large variability between subjects, a relatively large
variation in replicate samples within a subject may still
result in a favorable reliability coefficient.
The within-subject coefficient of variation (CV) was
calculated as the ratio of the within-subject standard devi-
ation and the overall mean, multiplied by 100 (expressed as
percentage). Smaller values of the CV indicate that the
within-subject variation is small compared to the mean. In
general, a CV of less than 10% is considered acceptable
[10]. Alternatively, an analytic CV one half of the biologic
CV may be useful in identifying change in analyte value
[11]. Due to the large number of analytes and the relatively
small sample size, no tests of statistical significance were
performed. The following descriptive comparisons between
sample types were identified as notable: differences in
reliability >15%, ratios of coefficient of variation < 0.667
or > 1.5, and ratios of means < 0.667 or > 1.5.
Results
Reliability and CV are similar across blood sample types,
with important exceptions
The majority of analytes produced similar results in all
sample types, both based on detection and on mea-
surements of reliability and CV between duplicate
samples (Figures 1, 2, and 3; Additional file 2: Table S2,
Additional file 3: Figure S1). Exceptions are listed in
Table 1 and highlighted in Figures 2 and 3.
Reliability and CV were not determined for twenty-
three of the 105 analytes (22%) because they were not
Figure 1 Scatterplots of coefficient of variation (CV) and reliability score for all consistently detectible analytes for 24 subjects.
Coefficient of variation (CV; left panel) and reliability (right panel) are plotted as shown for either serum and EDTA plasma (top row) or P100 and
EDTA plasma (bottom row). Outliers in these figures with either CV > 20% or reliability < 0.60 are discussed further in Table 1.
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within each of the three sample types (Table 1). Four
analytes, IL1A, IL1RN, IL12B, and OLR1 were consist-
ently detected in serum but not in plasma; conversely,
three analytes, fibrinogen [FGA_FGB_FGG], IFNG, and
MMP2 were consistently detected in plasma samples
but not serum. An additional 7 analytes (7%) were con-
sistently detected in at least one of the 3 sample types,
but had low reliability measurements (< 60%) or high
CV (> 20%) in the sample types that were consistently
detected.
Twelve analytes (11%) performed notably better in
serum versus EDTA plasma and another 11 better in
EDTA plasma than serum, based on descriptive cut-
points for differences of reliability and ratios of coeffi-
cient of variation values (see Table 1, Figures 1 and 2).
The majority of the analytes performed similarly in
EDTA plasma compared to P100 plasma (Figure 1).
Only one analyte (CCL4) performed better in P100
plasma relative to EDTA plasma, yet the difference was
modest (Additional file 2: Table S2). Eight analytes
showed notably better performance (lower CV) in EDTAplasma compared to P100 (Table 1). Reliability of EDTA
and P100 plasma was within 15% for all consistently
detectable analytes.
Absolute values vary across sample types
Except for analytes that were only detected in either
serum or plasma, the mean expression values differed
by > 1.5 fold between plasma and serum for 20 analytes
(19%) (analytes listed in Table 1; Additional file 2: Table
S2; Supplemental Figure 1 displays the mean and a dot
plot for each analyte and sample type). Of these, serum
produced higher values for 17 analytes (16%), while
plasma produced higher values for three (3%). We iden-
tified no notable differences in mean levels between
EDTA plasma and P100 plasma samples (data not
shown).
Individual analyte performance characteristics are not
consistent within multiplexes
Each multiplex had its own unique features related to
analytes detection and sample-type performance, which
are summarized in Table 2. Within each multiplex,
Figure 2 Plots indicating analytes with notable differences in
CV or reliability between serum and EDTA plasma for 24
subjects. A) The ratio of CV (serum:EDTA plasma) is plotted in rank
order from largest to smallest by analyte. Analytes with notably
better CV in EDTA plasma (ratio >1.5; lower CV in plasma) and
notably better CV in serum (CV ratio <0.667; lower CV in serum) are
indicated B) The difference in reliability score between serum and
plasma (serum minus plasma) is is plotted in rank order from largest
to smallest by analyte. Analytes with notably better reliability in
serum versus plasma (difference > +0.15) and better reliability in
EDTA plasma versus serum (difference < −0.015) are indicated.
Horizontal lines indicate descriptive cut-points used to define
notable performance.
Figure 3 Plot indicating analytes with notable differences in
mean levels between serum and EDTA plasma for 24 subjects.
The ratio of measured mean analyte levels (serum:EDTA plasma) is
plotted in rank order from largest to smallest by analyte. Analytes
with notably higher levels measured in serum (ratio >1.5) and EDTA
plasma (< 0.667) are indicated. Horizontal lines indicate descriptive
cut-points used to define notable differences.
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serum or plasma, with the exception of Myriad-RBM
multiplexes HMPC49 and HMPCORE1 where 3/5 and
12/17 analytes were not detectable or not reliably mea-
sured, respectively. Multiplex HMPCORE4 performed
with noticeably worse CV for most analytes compared to
other multiplexes, with only one analyte (GC) having a
CV <10%. Serum had noticeably better reliability and/or
CV for detected analytes in HCVD4, HMPC62 and
HMPC83; while plasma generally performed better for de-
tected analytes in HMP8, HMPC35, and HMPCORE4. For
multiplexes HMPC19, HMPCORE1, and HMPCORE2,certain represented analytes performed better in serum and
others in plasma. For HMPC42 and HMPC84, all sample
types performed similarly.
Discussion
Easily measurable biomarkers that mark complex disease
phenotypes, such as those found in COPD, would be ex-
tremely valuable for the purposes of diagnosis, treatment
individualization, patient selection for clinical trials, and
as surrogate markers for disease progression. While
the number of clinically available biomarkers for such
purposes remains low, it is likely to increase as new
biomarkers are discovered and as analytical methods
continue to improve. Blood is an ideal sample for bio-
marker collection given the comparative ease of collec-
tion. Depending upon the analyte to be measured, the
choice of serum versus plasma and analytical platform
can be critical decisions.
In terms of overall quantification and detectability, we
found that results using serum and plasma were similar
for most measured analytes. The four major exceptions
[OLR1, IFNG, MMP2, FGA_FGB_FGG (fibrinogen);
Table 1] are consistent with previous observations. Fi-
brinogen is depleted in serum, since it is removed during
the clotting process [12]. Poor detection of MMP2 in
the serum as compared to plasma is consistent with
some previous findings [8], but not others [13]. Our
finding that IFNG was measured at reduced levels in
serum compared to plasma is also consistent with pub-
lished findings [14]. The mechanism of this loss is not
clear, but the observation is critical for interpretation of
data describing the innate and adaptive immune re-
sponses in tissue, where pro-coagulant activity may
Table 1 Analytes identified that showed variation in measurement performance across blood sample types#
Detectability based on
percent of samples >
LLOQ
Detected in less than 50% of samples for all three
sample types
CCL3, CSF2, FABP3, HSPD1, IL10, IL12A/IL12B, IL17A, IL1B, IL2,
IL23B, IL3, IL4, IL5, IL6, IL7, INS_intact, INS_total, LTA, MDA-LDL,
MICA, NGF, S100B, TNF
Detected in >50% of serum samples but not in > 50%
of EDTA or P100 plasma samples
IL1A, IL1RN, IL12B, OLR1
Detected in >50% of EDTA and P100 plasma samples
but not in > 50% of serum samples
FGA_FGB_FGG, IFNG, MMP2
Measurability based
on reliability and CV
Reliability values <0.60 or CV (%)≥ 20 in all three sample
types in samples where one or more sample types
had >50% of samples > LLOQ.
ALB, CA9, IFNG, IL1RN, IL12B, SPINK1, TIMP1
Performed better* in EDTA plasma compared to serum ADIPOQ, AGER, ALB$, CCL16, CCL5, CRP, GC, HP, IgM, MMP9,
SERPINE1, VEGFA
Perform better & in serum compared to EDTA plasma ANGPT1, CA9$, CEACAM1, CCL2, CCL20, FAS, HGF, IL18, KITLG,
SERPINA3, THBD
Ratio of CV of P100:EDTA plasma > 1.5 ADIPOQ, CXCL9, IL18BP, IgM, PEACAM1, SPINK1$, SFTPD, VEGFA
Ratio of CV of P100:EDTA plasma < 0.667 CCL4
Measured values Mean levels > 1.5 fold higher in serum compared to
plasma
A2M, ANGPT1, BDNF, CCL11, CCL13, CCL2, CCL24, CCL5, HGF,
MMP3, LTF, SERPINE1, SFTPD, TGFB1_LAP, TIMP1$, TNFRSF11B,
VEGFA
Mean levels > 1.5 fold higher in plasma compared to
serum
CDH13, MMP9, SOD1
# When possible, the analytes are identified by the official gene symbol; Refer to Additional file 1: Table S1 for listing of all analyte designations.
*Better performance in EDTA plasma compared to serum is determined when either the ratio of CV serum:CV EDTA plasma >1.5 or the difference in the reliability
score for serum minus EDTA plasma < −0.15.
&Better performance in serum compared to EDTA plasma is determined when either the ratio of CV serum:CV plasma <0.667 or the difference in the reliability
score for serum minus EDTA plasma >0.15.
$Analytes with this designation had poor measurement characteristics in all three sample types as designated in the table as producing reliability values <0.60 or
CV (%) ≥ 20 in all three sample types.
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kine. Why OLR1 (oxidized low density lipoprotein re-
ceptor 1) was identified only in serum is not clear, but
the observation likely has analytical and/or biological
relevance. Thus, results of our studies are congruent
with other studies suggesting that platelet activation
alters concentrations of many analytes during sample
processing. This effect will increase serum values, rela-
tive to plasma, for factors that are released from platelets
or leukocytes during clotting, and conversely decrease
serum values, relative to plasma, for factors that co-
localize with clots.
We believe that similar biologic behaviour may explain
our results for the far larger number of analytes for
which the mean expression values differed (Supplemen-
tal Figure 1, Table 1) even though values > LLOQ were
measured for all sample types. For example, VEGFA and
SERPINE1 are known to be localized in platelet gran-
ules, and higher levels of these analytes in serum versus
plasma are expected [15,16]. The results of our studies
are congruent with other studies suggesting the role of
platelet activation in the release of many analytes during
sample processing. Interestingly, there was no strong
trend for higher mean levels to produce improved
performance in reliability or CV; in fact, several analytes
showed the reverse. Thus, alteration in analyte concentra-
tion due to blood coagulation during sample collectionpotentially interferes with the search for biomarkers that
correlate with disease processes by obscuring actual circu-
lating levels in the patients. Inhibition of platelet activation,
which can occur even in plasma during blood sample
processing, is the logic behind the development of CTAD
blood (plasma) collection tubes, which are designed to
prevent platelet activation [17].
Nevertheless, the study did not identify any notable
differences in mean analyte levels between EDTA plasma
and P100 plasma, despite the presence of protease inhib-
itors in the P100 blood collection tubes. These results
are similar to the findings of others using mass spectros-
copy and multiplex ELISA methods [18-20]. Enzymatic
degradation has been reported to occur during blood
collection and processing [5,21]; protease inhibitors have
stabilized the proteome in some studies [22]. However,
any on-going proteolysis may not necessarily result in
loss of antigenicity, the basis for the multiplex assays uti-
lized in this work. Rapid processing and careful storage
may also have prevented degradation in this study. The
substantial additional cost of the P100 plasma tubes
should be carefully weighed against their potential
benefit, and the results for the analytes tested here sup-
port the conclusion that P100 tubes are generally not
required.
Multiplexes are conceptually economical in terms of
cost, sample volume, or both. However, these economies








Microalbumin 1:1E6 1 Simplex, one-analyte only; requires substantial dilution; low reliability across duplicates in
all sample types.
HCVD4 1:5 5 2/5 analytes not detected; serum has better performance for 1/5 analytes.
HMP8 1:200 10 All analytes detected; plasma has better performance for 3/10 analytes; mean levels vary
between serum and plasma for 4/10 analytes.
HMPC19 1:5 6 All analytes detected; plasma has better performance for 1/6 analytes; serum has better
performance for 2/6 analytes.
HMPC35 1:5 7 2/7 analytes not detected; plasma has better performance for 1/7 analytes; serum has
better performance in 1/7 analytes.
HMPC42 1:5 8 All analytes detected; serum has better performance in 1/8 analytes.
HMPC49 1:5 5 3/5 analytes not detected consistently; serum has better performance in 1/5 analytes.
HMPC62 1:5 6 1/6 analytes not reliably detected; serum has better performance for 1/6 analytes; mean
levels higher in serum for 3/6 analytes.
HMPC83 1:5 9 All analytes detected in at least one sample type; serum has better performance in 2/9
analytes; mean level higher in serum for 3/9 and higher in plasma for 1/9 analytes.
HMPC84 1:100 7 All analytes detected; sample types behave similarly; mean level higher in serum for 1/7
analytes.
HMPCORE1 1:5 17 12/17 analytes not detected or not consistently detected; plasma shows better
performance for 1/17 analytes (only detected in plasma); serum has better performance
for 2/17 analytes; mean level higher in serum for 1/17 analytes.
HMPCORE2 1:5 16 5/16 analytes not consistently detected in any sample type; 2/16 analytes were only
consistently detected in serum; 2/16 analytes performed better in plasma. Mean level
higher in serum for 3/16 analytes.
HMPCORE4 1:200,000 8 All analytes detected; plasma has better performance for 4/8 analytes; CV > 10% for
a majority of analytes and sample types; higher overall CVs compared to other multi-
plexes. Highest dilution of all multiplexes
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valid, and reproducible results for the analytes of interest
to the study. Several factors should be considered when
selecting the most appropriate blood sample type for
this format. First, the specific analytes comprising the
multiplex should be weighed against disease processes
and biological questions. For example, in multiplex
HMPC19, FAS and HGF performed better in serum,
whereas CCL16 performed better in plasma. In such a
situation, the analytes of greatest research interest based
on underlying pathophysiology of the disease might
drive this choice of sample type. Second, the value of
economizing should be balanced against the necessity
for sensitivity. For example, the largest multiplex repre-
sented in this study was HMPCORE1, which consisted
of 17 analytes with links to inflammation or inflamma-
tory processes, which are relevant to COPD pathogen-
esis. In this pilot, 12/17 of these analytes were not
detected or not detected reliably > LLOQ in any of the
sample types. While this finding could indeed reflect the
lack of inflammation in the selected subjects, it more
likely results from loss of sensitivity compared to stand-
ard single analyte immuno assays. Finally, for assays
in which key analytes produce high CV, such as
HMPCORE4, likely due to the need to dilute the originalsamples many-fold to bring analyte levels within the levels
detected by the standard curve, the necessity of running
duplicates, or even triplicate samples should be considered.
In SPIROMICS, the high CV for CRP and fibrinogen are of
particular relevance given the previous studies evaluating
these proteins as biomarkers of disease status [23,24].
Conclusions
Despite the inability to detect some analytes, likely because
of limited sensitivity, the Myriad-RBM platform is useful
for biomarker profiling in SPIROMICS. For many of the
analytes evaluated in this study, the performance of the
multiplex assays using serum versus EDTA plasma versus
P100 plasma was similar. However, for certain potentially
critical analytes [(e. g., fibrinogen, MMP9, CRP [23,25]
reliability and/ or CV differed depending upon sample
source. Additionally, in our study, several analytes of im-
portance to COPD pathogenesis were measured but had a
high (>10%) CV between duplicate samples. The choice of
sample type and analytical platform must ultimately depend
on a balance between availability and the need for sensitiv-
ity and reliability. The data provided in this study will be
useful to other investigators considering the use of serum
or plasma for specific tests utilizing the Myriad-RBM or
other similar platforms.
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Additional file 1: Table S1. Analytes measured in this manuscript. The
analytes are listed in alphabetical order by abbreviation, which
corresponds when possible to the official gene symbol for the analyte
that is being measured. Alternate identifications (ID) are provided
because many of these analytes are known by several names in the
literature and in common usage. The plex designation is also provided.
The designation of the plex comes directly from the name of the plex
provided by Myriad-RBM. Readers are provided the plex designation to
aid in the perusal of Additional file 2: Table S2.
Additional file 2: Table S2. Analyte performance in serum, EDTA
plasma (EDTA), and 100 plasma (P100) for 24 subjects. The analytes are
arranged by their organization on the various multiplex assays (plex;
column 1) as conducted by Myriad-RBM. LLOQ = lower limit of quantifica-
tion as defined in the text. The total number of subjects was N = 24. Sam-
ples from each subjectwere run in duplicate. % < LLOQ indicates the
percent of samples below the LLOQ. “N of pairs” is the number of sub-
jects in which both replicates were ≥ LLOQ. Descriptive statistics were
only calculated if “N of pairs” was ≥12. nd = not determined. SD = the
within subject standard deviation as defined in methods. Reliability and
coefficient of variation (CV) were determined as described in the
methods. Higher reliability and lower CV are indicative of better perform-
ance. Comments are provided to highlight aspects specific to each indi-
vidual analyte. “Better” performance as described in the Comments
column was determined as a difference in reliability >0.15 and/or a CV ra-
tio between serum and EDTA plasma of >1.5 (better performance in
EDTA plasma) or <0.667 (better performance in serum). Analytes with reli-
ability <60 or CV (%) > 20 for all consistently detectible blood sample
types, analytes whose mean reported valued differ between serum and
EDTA plasma, and specific differences noted between P100 and EDTA
plasma are also highlighted in the “Comments.”
Additional file 3: Figure S1. Plot of measured levels for each analyte
and blood sample type for 24 subjects. Plots of the measured levels for
all analytes in the three blood sample types. Mean expression levels are
displayed as a solid line. Where applicable, the LLOQ is displayed as a
dashed line. Panels are sorted alphabetically by the analyte abbreviation
within each multiplex.
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